Upward adjustments in BRCA1 mutation-prediction scores were made for grade 3 ductal cancers, estrogen receptor (ER), and triple-negative tumors, and downward adjustments in the score were made for grade 1 tumors, lobular cancer, ductal or lobular carcinoma in situ, noninvasive breast cancer, and ER/HER2 positivity, as described previously [18]. The gene discussed is ERBB2; the disease is breast carcinoma.